08th April 2022 | Pharma Updates
Pfizer announced a voluntary retirement scheme for field staff
Pfizer, the pharmaceutical and biotechnology conglomerate, announced a voluntary retirement scheme for its field personnel on Thursday. Pfizer claimed in a BSE filing that it will help all eligible coworkers.
Lupin completed its acquisition of Anglo French Drugs & Industries' brand portfolio
Lupin announced the completion of its acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited and acquisition will help the company’s India formulation business.
USFDA hopes to make a decision on strain selection for COVID boosters by June
U.SFDA officials said the agency hopes to make a decision by June on whether to adjust the design of COVID-19 vaccines to battle future variants, even if it lacks all of the data needed to assess their efficacy.
Pfizer did not bribe the FDA to get its COVID-19 vaccine approved
Some social media users are incorrectly misrepresenting a document indicating a $2.8 million payment from Pfizer to the US Food and Drug Administration as a “bribe” for the company’s COVID-19 vaccine approval.
US withdraws GSK's COVID medication as its omicron sibling dominates instances
The IV medication developed by GlaxoSmithKline for COVID-19 should no longer be administered because it is likely ineffective against the omicron subvariant, which currently accounts for the majority of cases in the United States.
Next-generation AI cardiac imaging platform with additional FDA-approved modules
Arterys announced the inclusion of many new features to their artificial intelligence-enhanced cardiac MRI technology, as well as an additional FDA clearance for two quantification modules.
Alembic Pharma received preliminary approval from USFDA for Dabigatran Etexilate capsules
Alembic Pharma reported that USFDA has tentatively approved its Abbreviated New Drug Application for Dabigatran Etexilate capsules, 75 mg, 110 mg, and 150 mg.
The final CMS Aducanumab decision confines coverage to clinical trials only
In a final decision on funding for the controversial Alzheimer’s medicine aducanumab, government regulators mostly held to their initial proposal of limiting Medicare reimbursement to patients enrolled in clinical studies.
Sucralfate Oral Suspension Receives FDA Approval
Clayton Pharmaceuticals announced that Sucralfate Oral Suspension with Competitive Generic Therapy (CGT) designation has obtained FDA approval.
Dexmedetomidine approved by the FDA for Agitation
Dexmedetomidine (Igalmi, BioXcel Therapeutics) sublingual film has been approved by the FDA for the treatment of individuals with agitation associated with bipolar disorders 1 and 2 and schizophrenia.